Drug Approval | December 23, 2025
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
Full approval will depend on verification of clinical benefit in a confirmatory trial
Full approval will depend on verification of clinical benefit in a confirmatory trial
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Subscribe To Our Newsletter & Stay Updated
